Collaborative Power of Nrf2 and PPAR γ Activators against Metabolic and Drug-Induced Oxidative Injury

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Lee, Choongho ^a  

^a Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; MAMMALS;

AMELIORATING EFFECT; ANTIOXIDATIVE DEFENSE SYSTEMS; METABOLIC DISORDERS; OXIDATIVE DAMAGE; OXIDATIVE INJURY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PHARMACOLOGICAL ACTIVATOR; REACTIVE OXYGEN SPECIES;

METABOLISM;

15 DEOXY 12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 O LAURYLGLYCERYL ASCORBATE; ALPHA METHYLENE GAMMA LACTONE DERIVATIVE; ALPHA TOCOPHEROL; ANKAFLAVIN; ARYLIDENE THIAZOLIDINEDION; BARDOXOLONE METHYL; CAROTENOID; CURCUMIN; CYCLOPENTENE DERIVATIVE; EPIGALLOCATECHIN GALLATE; FATTY ACID DERIVATIVE; GENISTEIN; GLYCYRRHETINIC ACID; GRAPTOPETALUM PARAGUAYENSE; MANGIFERIN; MONASCIN; NITRATED FATTY ACID; NITROALKENE FATTY ACID; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN J2; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROSIGLITAZONE; TRANSCRIPTION FACTOR NRF2; TROGLITAZONE; UMBELLIFERONE; UNCLASSIFIED DRUG; DRUG;

ANTIOXIDANT ACTIVITY; COMPLEX FORMATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TARGETING; GENE EXPRESSION; HUMAN; METABOLIC DISORDER; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

DAMAGE; MEDICINE; OXYGEN; SPECIES IDENTIFICATION;

ANIMALS; HUMANS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; PPAR GAMMA; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85029788883     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/1378175     Document Type: Review

References (110)

1. M. Hayyan, M. A. Hashim, I. M. AlNashef, "Superoxide ion: Generation and chemical implications, " Chemical Reviews, vol. 116, no. 5, pp. 3029-3085, 2016.
2. M. Kvandova, M. Majzunova, I. Dovinova, "The role of PPARgamma in cardiovascular diseases, " Physiological Research, vol. 65, Supplementum 3, pp. S343-S363, 2016.
3. H. R. Griffiths, "ROS as signalling molecules in T cells-evidence for abnormal redox signalling in the autoimmune disease, rheumatoid arthritis, " Redox Report, vol. 10, no. 6, pp. 273-280, 2005.
4. B. D'Autreaux and M. B. Toledano, "ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis, " Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813-824, 2007.
5. J. Kim and Y. S. Keum, "NRF2, a key regulator of antioxidants with two faces towards cancer, " Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 2746457, 7 pages, 2016.
6. F. L. Muller, M. S. Lustgarten, Y. Jang, A. Richardson, H. Van Remmen, "Trends in oxidative aging theories, " Free Radical Biology & Medicine, vol. 43, no. 4, pp. 477-503, 2007.
7. J. M. Van Raamsdonk and S. Hekimi, "Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans, " PLoS Genetics, vol. 5, no. 2, article e1000361, 2009.
8. J. M. Carney, P. E. Starke-Reed, C. N. Oliver, et al., "Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, loss in temporal and spatial memory by chronic administration of the spin-trapping compound Ntert-butyl-alpha-phenylnitrone, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3633-3636, 1991.
9. E. R. Stadtman, "Protein oxidation and aging, " Science, vol. 257, no. 5074, pp. 1220-1224, 1992.
10. J. Liu, E. Head, A. M. Gharib, et al., "Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 4, pp. 2356-2361, 2002.
11. S. C. Gupta, D. Hevia, S. Patchva, B. Park, W. Koh, B. B. Aggarwal, "Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, therapy, " Antioxidants & Redox Signaling, vol. 16, no. 11, pp. 1295-1322, 2012.
12. U. Forstermann, N. Xia, H. Li, "Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis, " Circulation Research, vol. 120, no. 4, pp. 713-735, 2017.
13. A. Konior, A. Schramm, M. Czesnikiewicz-Guzik, T. J. Guzik, "NADPH oxidases in vascular pathology, " Antioxidants & Redox Signaling, vol. 20, no. 17, pp. 2794-2814, 2014.
14. P. Newsholme, V. F. Cruzat, K. N. Keane, R. Carlessi, P. I. d. Bittencourt Jr., "Molecular mechanisms of ROS production and oxidative stress in diabetes, " The Biochemical Journal, vol. 473, no. 24, pp. 4527-4550, 2016.
15. K. Kandola, A. Bowman, M. A. Birch-Machin, "Oxidative stress-a key emerging impact factor in health, ageing, lifestyle and aesthetics, " International Journal of Cosmetic Science, vol. 37, Supplement 2, pp. 1-8, 2015.
16. A. G. Miranda-Diaz, L. Pazarin-Villasenor, F. G. Yanowsky-Escatell, J. Andrade-Sierra, "Oxidative stress in diabetic nephropathy with early chronic kidney disease, " Journal of Diabetes Research, vol. 2016, Article ID 7047238, 7 pages, 2016.
17. J. X. Jiang and N. J. Torok, "NADPH oxidases in chronic liver diseases, " Advances in Hepatology, vol. 2014, Article ID 742931, 8 pages, 2014.
18. P. Moi, K. Chan, I. Asunis, A. Cao, Y. W. Kan, "Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region, " Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 9926-9930, 1994.
19. M. Kobayashi, L. Li, N. Iwamoto, et al., "The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds, " Molecular and Cellular Biology, vol. 29, no. 2, pp. 493-502, 2009.
20. K. Itoh, N. Wakabayashi, Y. Katoh, et al., "Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain, " Genes & Development, vol. 13, no. 1, pp. 76-86, 1999.
21. A. Kobayashi, M. I. Kang, H. Okawa, et al., "Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2, " Molecular and Cellular Biology, vol. 24, no. 16, pp. 7130-7139, 2004.
22. A. Kobayashi, M. I. Kang, Y. Watai, et al., "Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1, " Molecular and Cellular Biology, vol. 26, no. 1, pp. 221-229, 2006.
23. B. N. Das, Y. W. Kim, Y. S. Keum, "Mechanisms of Nrf2/Keap1-dependent phase II cytoprotective and detoxifying gene expression and potential cellular targets of chemopreventive isothiocyanates, " Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 839409, 7 pages, 2013
24. H. Y. Cho, S. P. Reddy, A. Debiase, M. Yamamoto, S. R. Kleeberger, "Gene expression profiling of NRF2-mediated protection against oxidative injury, " Free Radical Biology & Medicine, vol. 38, no. 3, pp. 325-343, 2005.
25. W. A. Solis, T. P. Dalton, M. Z. Dieter, et al., "Glutamate-cysteine ligase modifier subunit: Mouse Gclm gene structure and regulation by agents that cause oxidative stress, " Biochemical Pharmacology, vol. 63, no. 9, pp. 1739-1754, 2002.
26. R. Venugopal and A. K. Jaiswal, "Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:-quinone oxidoreductase1 gene, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14960-14965, 1996.
27. Y. H. Jeong, J. S. Park, D. H. Kim, H. S. Kim, "Lonchocarpine increases Nrf2/ARE-mediated antioxidant enzyme expression by modulating AMPK and MAPK signaling in brain astrocytes, " Biomolecules & Therapeutics (Seoul), vol. 24, no. 6, pp. 581-588, 2016.
28. C. H. Jin, Y. K. So, S. N. Han, J. B. Kim, "Isoegomaketone upregulates heme oxygenase-1 in RAW264.7 cells via ROS/p38 MAPK/Nrf2 pathway, " Biomolecules & Therapeutics (Seoul), vol. 24, no. 5, pp. 510-516, 2016.
29. W. Miao, L. Hu, P. J. Scrivens, G. Batist, "Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: Direct cross-talk between phase I and II drug-metabolizing enzymes, " The Journal of Biological Chemistry, vol. 280, no. 21, pp. 20340-20348, 2005.
30. M. Yang, Y. Yao, G. Eades, Y. Zhang, Q. Zhou, "MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism, " Breast Cancer Research and Treatment, vol. 129, no. 3, pp. 983-991, 2011.
31. G. Eades, M. Yang, Y. Yao, Y. Zhang, Q. Zhou, "miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells, " The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40725-40733, 2011.
32. S. B. Cullinan and J. A. Diehl, "Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway, " The International Journal of Biochemistry & Cell Biology, vol. 38, no. 3, pp. 317-332, 2006.
33. H. C. Huang, T. Nguyen, C. B. Pickett, "Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription, " The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42769-42774, 2002.
34. Y. Katoh, K. Itoh, E. Yoshida, M. Miyagishi, A. Fukamizu, M. Yamamoto, "Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, synergistically activate transcription, " Genes to Cells, vol. 6, no. 10, pp. 857-868, 2001.
35. Z. Sun, Y. E. Chin, D. D. Zhang, "Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response, " Molecular and Cellular Biology, vol. 29, no. 10, pp. 2658-2672, 2009.
36. C. M. Clements, R. S. McNally, B. J. Conti, T. W. Mak, J. P. Ting, "DJ-1, a cancer-A nd Parkinson's diseaseassociated protein, stabilizes the antioxidant transcriptional master regulator Nrf2, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15091-15096, 2006.
37. Y. Zheng, A. Morris, M. Sunkara, J. Layne, M. Toborek, B. Hennig, "Epigallocatechin-gallate stimulates NF-E2-related factor and heme oxygenase-1 via caveolin-1 displacement, " The Journal of Nutritional Biochemistry, vol. 23, no. 2, pp. 163-168, 2012.
38. W. Chen, Z. Sun, X. J. Wang, et al., "Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response, " Molecular Cell, vol. 34, no. 6, pp. 663-673, 2009.
39. J. D. Hayes and A. T. Dinkova-Kostova, "The Nrf2 regulatory network provides an interface between redox and intermediary metabolism, " Trends in Biochemical Sciences, vol. 39, no. 4, pp. 199-218, 2014.
40. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, W. Wahli, "From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions, " Progress in Lipid Research, vol. 45, no. 2, pp. 120-159, 2006.
41. J. Berger and D. E. Moller, "The mechanisms of action of PPARs, " Annual Review of Medicine, vol. 53, pp. 409-435, 2002.
42. A. Belfiore, M. Genua, R. Malaguarnera, "PPARgamma agonists and their effects on IGF-I receptor signaling: Implications for cancer, " PPAR Research, vol. 2009, Article ID 830501, 18 pages, 2009.
43. K. R. Dunning, M. R. Anastasi, V. J. Zhang, D. L. Russell, R. L. Robker, "Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists, " PLoS One, vol. 9, no. 2, article e87327, 2014.
44. I. Rusyn, M. L. Rose, H. K. Bojes, R. G. Thurman, "Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators, " Antioxidants & Redox Signaling, vol. 2, no. 3, pp. 607-621, 2000.
45. T. Varga, Z. Czimmerer, L. Nagy, "PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation, " Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 1007-1022, 2011.
46. A. Y. Swati Agarwal and R. K. Chaturvedi, "Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders, " Biochemical and Biophysical Research Communications, vol. 483, no. 4, pp. 1166-1177, 2017.
47. B. Desvergne and W. Wahli, "Peroxisome proliferatoractivated receptors: Nuclear control of metabolism, " Endocrine Reviews, vol. 20, no. 5, pp. 649-688, 1999.
48. S. Polvani, M. Tarocchi, A. Galli, "PPARgamma and oxidative stress: Con(beta) catenating NRF2 and FOXO, " PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012.
49. G. Kronke, A. Kadl, E. Ikonomu, et al., "Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors, " Arteriosclerosis, Thrombosis, Vascular Biology, vol. 27, no. 6, pp. 1276-1282, 2007.
50. X. Wang, Z. Wang, J. Z. Liu, et al., "Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte, " Toxicology in Vitro, vol. 25, no. 4, pp. 839-847, 2011.
51. E. D. Rosen and B. M. Spiegelman, "PPARgamma: A nuclear regulator of metabolism, differentiation, cell growth, " The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731-37734, 2001.
52. J. R. Jones, C. Barrick, K. A. Kim, et al., "Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6207-6212, 2005.
53. D. B. Savage, "PPAR gamma as a metabolic regulator: Insights from genomics and pharmacology, " Expert Reviews in Molecular Medicine, vol. 7, no. 1, pp. 1-16, 2005.
54. S. M. Rangwala and M. A. Lazar, "Peroxisome proliferatoractivated receptor gamma in diabetes and metabolism, " Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 331-336, 2004.
55. H. P. Koeffler, "Peroxisome proliferator-activated receptor gamma and cancers, " Clinical Cancer Research, vol. 9, no. 1, pp. 1-9, 2003.
56. Y. Li, Y. Qi, T. H. Huang, J. Yamahara, B. D. Roufogalis, "Pomegranate flower: A unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties, " Diabetes, Obesity & Metabolism, vol. 10, no. 1, pp. 10-17, 2008.
57. H. Takano and I. Komuro, "Roles of peroxisome proliferatoractivated receptor gamma in cardiovascular disease, " Journal of Diabetes and Its Complications, vol. 16, no. 1, pp. 108-114, 2002.
58. Q. Shen, C. Chitchumroonchokchai, J. L. Thomas, et al., "Adipocyte reporter assays: Application for identification of anti-inflammatory and antioxidant properties of mangosteen xanthones, " Molecular Nutrition & Food Research, vol. 58, no. 2, pp. 239-247, 2014.
59. L. Dubuquoy, C. Rousseaux, X. Thuru, et al., "PPARgamma as a new therapeutic target in inflammatory bowel diseases, " Gut, vol. 55, no. 9, pp. 1341-1349, 2006.
60. B. Vandewalle, E. Moerman, B. Lefebvre, et al., "PPARgamma-dependent and-independent effects of rosiglitazone on lipotoxic human pancreatic islets, " Biochemical and Biophysical Research Communications, vol. 366, no. 4, pp. 1096-1101, 2008.
61. R. C. Reddy and T. J. Standiford, "Nrf2 and PPAR{gamma}: PPARtnering against oxidant-induced lung injury, " American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 134-135, 2010.
62. X. Zhao, Y. Zhang, R. Strong, J. C. Grotta, J. Aronowski, "15d-Prostaglandin J2 activates peroxisome proliferatoractivated receptor-gamma, promotes expression of catalase, reduces inflammation, behavioral dysfunction, neuronal loss after intracerebral hemorrhage in rats, " Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 6, pp. 811-820, 2006.
63. G. Ding, M. Fu, Q. Qin, et al., "Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage, " Cardiovascular Research, vol. 76, no. 2, pp. 269-279, 2007.
64. J. Huang, I. Tabbi-Anneni, V. Gunda, L. Wang, "Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism, " American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 299, no. 6, pp. G1211-G1221, 2010.
65. H. Y. Cho, W. Gladwell, X. Wang, et al., "Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice, " American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 170-182, 2010.
66. B. N. Chorley, M. R. Campbell, X. Wang, et al., "Identification of novel NRF2-regulated genes by ChIP-Seq: Influence on retinoid X receptor alpha, " Nucleic Acids Research, vol. 40, no. 15, pp. 7416-7429, 2012.
67. Y. Y. Wang, Y. X. Yang, H. Zhe, Z. X. He, S. F. Zhou, "Bardoxolone methyl (CDDO-Me) as a therapeutic agent: An update on its pharmacokinetic and pharmacodynamic properties, " Drug Design, Development and Therapy, vol. 8, pp. 2075-2088, 2014.
68. B. L. Probst, I. Trevino, L. McCauley, et al., "RTA 408, a novel synthetic triterpenoid with broad anticancer and antiinflammatory activity, " PLoS One, vol. 10, no. 4, article e0122942, 2015.
69. Q. Q. Wu, Y. Wang, M. Senitko, et al., "Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, HO-1, " American Journal of Physiology-Renal Physiology, vol. 300, no. 5, pp. F1180-F1192, 2011.
70. D. de Zeeuw, T. Akizawa, P. Audhya, et al., "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease, " The New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503, 2013.
71. A. S. Jimenez-Osorio, S. Gonzalez-Reyes, J. Pedraza-Chaverri, "Natural Nrf2 activators in diabetes, " Clinica Chimica Acta, vol. 448, pp. 182-192, 2015.
72. D. Olagnier, R. A. Lavergne, E. Meunier, et al., "Nrf2, a PPARgamma alternative pathway to promote CD36 expression on inflammatory macrophages: Implication for malaria, " PLoS Pathogens, vol. 7, no. 9, article e1002254, 2011.
73. P. N. Mimche, E. Thompson, D. Taramelli, L. Vivas, "Curcumin enhances non-opsonic phagocytosis of Plasmodium falciparum through up-regulation of CD36 surface expression on monocytes/macrophages, " The Journal of Antimicrobial Chemotherapy, vol. 67, no. 8, pp. 1895-1904, 2012.
74. E. H. Kim and Y. J. Surh, "15-Deoxy-delta12, 14-prostaglandin J2 as a potential endogenous regulator of redoxsensitive transcription factors, " Biochemical Pharmacology, vol. 72, no. 11, pp. 1516-1528, 2006.
75. R. E. Haskew-Layton, J. B. Payappilly, H. Xu, S. A. Bennett, R. R. Ratan, "15-Deoxy-delta12, 14-prostaglandin J2 (15d-PGJ2) protects neurons from oxidative death via an Nrf2 astrocyte-specific mechanism independent of PPARgamma, " Journal of Neurochemistry, vol. 124, no. 4, pp. 536-547, 2013.
76. P. Gong, D. Stewart, B. Hu, et al., "Activation of the mouse heme oxygenase-1 gene by 15-deoxy-delta(12, 14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2, " Antioxidants & Redox Signaling, vol. 4, no. 2, pp. 249-257, 2002.
77. M. J. Gorczynski, P. K. Smitherman, T. E. Akiyama, et al., "Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: Importance of nitration position and degree of unsaturation, " Journal of Medicinal Chemistry, vol. 52, no. 15, pp. 4631-4639, 2009.
78. D. J. Bates, P. K. Smitherman, A. J. Townsend, S. B. King, C. S. Morrow, "Nitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARgamma-dependent transcription by distinct signaling pathways and with significantly different potencies, " Biochemistry, vol. 50, no. 36, pp. 7765-7773, 2011.
79. A. Trostchansky and H. Rubbo, "Nitrated fatty acids: Mechanisms of formation, chemical characterization, biological properties, " Free Radical Biology & Medicine, vol. 44, no. 11, pp. 1887-1896, 2008.
80. A. T. Reddy, S. P. Lakshmi, R. C. Reddy, "The nitrated fatty acid 10-nitro-oleate diminishes severity of LPSinduced acute lung injury in mice, " PPAR Research, vol. 2012, Article ID 617063, 12 pages, 2012.
81. J. Ohsumi, S. Sakakibara, J. Yamaguchi, et al., "Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells, " Endocrinology, vol. 135, no. 5, pp. 2279-2282, 1994.
82. L. A. Faine, M. Rudnicki, F. A. Cesar, et al., "Anti-inflammatory and antioxidant properties of a new arylidenethiazolidinedione in macrophages, " Current Medicinal Chemistry, vol. 18, no. 22, pp. 3351-3360, 2011.
83. Z. N. Liu, M. Zhao, Q. Zheng, H. Y. Zhao, W. J. Hou, S. L. Bai, "Inhibitory effects of rosiglitazone on paraquatinduced acute lung injury in rats, " Acta Pharmacologica Sinica, vol. 34, no. 10, pp. 1317-1324, 2013.
84. P. H. Shih, S. L. Hwang, C. T. Yeh, G. C. Yen, "Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways, " Journal of Agricultural and Food Chemistry, vol. 60, no. 11, pp. 2924-2933, 2012.
85. X. Zhang, W. E. Zhao, L. Hu, L. Zhao, J. Huang, "Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells, " Archives of Biochemistry and Biophysics, vol. 512, no. 1, pp. 96-106, 2011.
86. P. J. Beisswenger, "Methylglyoxal in diabetes: Link to treatment, glycaemic control and biomarkers of complications, " Biochemical Society Transactions, vol. 42, no. 2, pp. 450-456, 2014.
87. W. H. Hsu, B. H. Lee, Y. Y. Chang, Y. W. Hsu, T. M. Pan, "A novel natural Nrf2 activator with PPARgamma-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia, " Toxicology and Applied Pharmacology, vol. 272, no. 3, pp. 842-851, 2013.
88. W. H. Hsu, B. H. Lee, C. H. Li, Y. W. Hsu, T. M. Pan, "Monascin and AITC attenuate methylglyoxal-induced PPARgamma phosphorylation and degradation through inhibition of the oxidative stress/PKC pathway depending on Nrf2 activation, " Journal of Agricultural and Food Chemistry, vol. 61, no. 25, pp. 5996-6006, 2013.
89. W. H. Hsu and T. M. Pan, "Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp, " Applied Microbiology and Biotechnology, vol. 98, no. 11, pp. 4853-4863, 2014.
90. B. H. Lee, W. H. Hsu, Y. Y. Chang, H. F. Kuo, Y. W. Hsu, T. M. Pan, "Ankaflavin: A natural novel PPARgamma agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo, " Free Radical Biology & Medicine, vol. 53, no. 11, pp. 2008-2016, 2012.
91. J. T. Kim, S. Barua, H. Kim, et al., "Absorption study of genistein using solid lipid microparticles and nanoparticles: Control of oral bioavailability by particle sizes, " Biomolecules & Therapeutics (Seoul), vol. 25, no. 4, pp. 452-459, 2017.
92. T. Zhang, F. Wang, H. X. Xu, et al., "Activation of nuclear factor erythroid 2-related factor 2 and PPARgamma plays a role in the genistein-mediated attenuation of oxidative stress-induced endothelial cell injury, " The British Journal of Nutrition, vol. 109, no. 2, pp. 223-235, 2013.
93. M. G. Traber and J. Atkinson, "Vitamin E, antioxidant and nothing more, " Free Radical Biology & Medicine, vol. 43, no. 1, pp. 4-15, 2007.
94. P. Bozaykut, B. Karademir, B. Yazgan, et al., "Effects of vitamin E on peroxisome proliferator-activated receptor gamma and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis, " Free Radical Biology & Medicine, vol. 70, pp. 174-181, 2014.
95. V. Karuppagounder, S. Arumugam, R. A. Thandavarayan, et al., "Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation, " International Immunopharmacology, vol. 28, no. 1, pp. 154-159, 2015.
96. V. K. Gounder, S. Arumugam, W. Arozal, et al., "Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats, " International Immunopharmacology, vol. 18, no. 2, pp. 282-289, 2014.
97. A. C. Le Lamer, H. Authier, I. Rouaud, et al., "Protolichesterinic acid derivatives: Alpha-methylene-gamma-lactones as potent dual activators of PPARgamma and Nrf2 transcriptional factors, " Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 16, pp. 3819-3822, 2014.
98. N. Scheinfeld, "Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexateinduced skin eruptions, " Dermatology Online Journal, vol. 12, no. 7, p. 15, 2006.
99. D. H. Solomon, J. M. Kremer, M. Fisher, et al., "Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs, " Seminars in Arthritis and Rheumatism, vol. 43, no. 4, pp. 489-497, 2014.
100. S. M. Abd El-Twab, W. G. Hozayen, O. E. Hussein, A. M. Mahmoud, "18beta-Glycyrrhetinic acid protects against methotrexate-induced kidney injury by up-regulating the Nrf2/ARE/HO-1 pathway and endogenous antioxidants, " Renal Failure, vol. 38, no. 9, pp. 1516-1527, 2016.
101. T. M. Motawi, N. A. Sadik, A. Refaat, "Cytoprotective effects of DL-alpha-lipoic acid or squalene on cyclophosphamide-induced oxidative injury: An experimental study on rat myocardium, testicles and urinary bladder, " Food and Chemical Toxicology, vol. 48, no. 8-9, pp. 2326-2336, 2010.
102. A. M. Mahmoud and H. S. Al Dera, "18beta-Glycyrrhetinic acid exerts protective effects against cyclophosphamideinduced hepatotoxicity: Potential role of PPARgamma and Nrf2 upregulation, " Genes & Nutrition, vol. 10, no. 6, p. 41, 2015.
103. T. Ye, J. Zhen, Y. Du, et al., "Green tea polyphenol (-)-epigallocatechin-3-gallate restores Nrf2 activity and ameliorates crescentic glomerulonephritis, " PLoS One, vol. 10, no. 3, article e0119543, 2015.
104. M. Mahmoud-Awny, A. S. Attia, M. F. Abd-Ellah, H. S. El-Abhar, "Mangiferin mitigates gastric ulcer in ischemia/reperfused rats: Involvement of PPAR-gamma, NF-kappaB and Nrf2/HO-1 signaling pathways, " PLoS One, vol. 10, no. 7, article e0132497, 2015.
105. Y. Katsuyama, T. Tsuboi, N. Taira, M. Yoshioka, H. Masaki, "3-O-Laurylglyceryl ascorbate activates the intracellular antioxidant system through the contribution of PPAROxidative gamma and Nrf2, " Journal of Dermatological Science, vol. 82, no. 3, pp. 189-196, 2016.
106. A. M. Mahmoud, M. O. Germoush, M. F. Alotaibi, O. E. Hussein, "Possible involvement of Nrf2 and PPARgamma up-regulation in the protective effect of umbelliferone against cyclophosphamide-induced hepatotoxicity, " Biomedicine & Pharmacotherapy, vol. 86, pp. 297-306, 2017.
107. A. Negre-Salvayre, R. Salvayre, N. Auge, R. Pamplona, M. Portero-Otin, "Hyperglycemia and glycation in diabetic complications, " Antioxidants & Redox Signaling, vol. 11, no. 12, pp. 3071-3109, 2009.
108. S. Schiekofer, M. Andrassy, J. Chen, et al., "Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, nuclear factor kappaB in PBMCs, " Diabetes, vol. 52, no. 3, pp. 621-633, 2003.
109. B. H. Lee, C. C. Lee, Y. H. Cheng, W. C. Chang, W. H. Hsu, S. C. Wu, "Graptopetalum paraguayense and resveratrol ameliorates carboxymethyllysine (CML)-induced pancreas dysfunction and hyperglycemia, " Food and Chemical Toxicology, vol. 62, pp. 492-498, 2013.
110. D. Serra, L. M. Almeida, T. C. Dinis, "Anti-inflammatory protection afforded by cyanidin-3-glucoside and resveratrol in human intestinal cells via Nrf2 and PPAR-gamma: Comparison with 5-aminosalicylic acid, " Chemico-Biological Interactions, vol. 260, pp. 102-109, 2016